Research
Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
Faeth Therapeutics (FTH) has an average rating of buy and mean price target of $56.67, according to analysts polled by FactSet.
$FTH
$FTH
8 stories mentioning FTHUpdated 7d ago
Every FINWIRES story that references FTH, newest first.
What are analysts saying about FTH?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on FTH?
Research
TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
Faeth Therapeutics (FTH) has an average rating of buy and mean price target of $54.64, according to analysts polled by FactSet.
$FTH
Research
Needham Initiates Faeth Therapeutics at Buy With $56 Price Target
Faeth Therapeutics (FTH) has an average rating of buy and mean price target of $54.64, according to analysts polled by FactSet.
$FTH
Research
Raymond James Initiates Faeth Therapeutics at Outperform
Faeth Therapeutics (FTH) has an average rating of buy and mean price target of $54.88, according to analysts polled by FactSet.
$FTH
Wire
Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says
Faeth Therapeutics' (FTH) investigational cancer drug Piktor has a differentiated potential and may see 24% upside from trial results in Q4, followed by breast cancer data next year that may unlock additional value, Oppenheimer said in a note emailed Tuesday.Oppenheimer said it is estimating risk-adjusted total peak sales of about $1.6 billion.The recent approval by the US Food and Drug Administration of Celcuity's (CELC) Revtorpyk for breast cancer "validates the multi-node mechanism," Oppenheimer said."We believe this validation supports Piktor's probability of success in both breast cancer and endometrial cancer," the note said.The investment firm added Piktor "could capture meaningful share in community oncology settings with efficacy similar to Revtorpyk."Oppenheimer started coverage of Faeth Therapeutics with an outperform rating and $60 price target.Price: $28.44, Change: $-0.80, Percent Change: -2.74%
$FTH
Research
Oppenheimer Initiates Faeth Therapeutics at Outperform
Faeth Therapeutics (FTHM) has an average rating of buy and mean price target of $54.71, according to analysts polled by FactSet.
$FTH
Research
Baird Initiates Faeth Therapeutics at Outperform With $57 Price Target
Faeth Therapeutics (FTHM) has an average rating of buy and mean price target of $54.40, according to analysts polled by FactSet.
$FTH
Research
HC Wainwright Initiates Faeth Therapeutics at Buy With $60 Price Target
$FTH
